83% of respondents with Acute COVID were satisfied; 68% of
respondents with Long COVID were satisfied
NEW
YORK and TEL AVIV,
Israel, June 24, 2022 /PRNewswire-PRWeb/ -- Todos
Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics
and related solutions company, today announced preliminary data
from its majority-owned joint venture 3CL Pharma Ltd.'s ongoing
IRB-waived sponsored market research study of the commercial use of
Tollovid® as a dietary supplement. Among the first 41 respondents,
of whom 78% were fully vaccinated against COVID-19, 13 reported
that they began to use Tollovid when they were diagnosed with
active COVID infection, whereas 28 respondents reported that they
used Tollovid to address their Long COVID symptoms. 15 of the Long
COVID respondents had experienced symptoms for up to 9 months
('Short' Long COVID), and 12 of the Long COVID respondents reported
having symptoms for over 9 months ('Chronic' Long COVID). 18 of the
24 respondents who answered the question "Who diagnosed your Long
COVID?" indicated that they were diagnosed by a medical
professional. The preliminary results of the market research study
are marked in the table.
"We are pleased with the preliminary results from this sponsored
market research study, that show the majority of our customers are
satisfied with Tollovid," said Dr. Dorit
Arad, Founder and Chief Scientific Officer at 3CL Pharma.
"As we add to the growing body of information related to COVID,
Long COVID and 3CL protease inhibitor products, we believe the
knowledge gained from this market research study will allow us to
tailor our offering to meet the needs of the immune competent (not
immune compromised) and Long COVID communities, who currently have
no 3CL protease inhibitor options on the market."
"The learnings gathered from the use of our dietary supplement
Tollovid will also allow us to design future Chronic Long COVID
clinical trials for our therapeutic drug candidate Tollovir™, which
is currently being prepared to enter a Phase 2/3 pivotal clinical
study in hospitalized COVID patients," said Gerald Commissiong, CEO at Todos Medical and
Interim CEO at 3CL Pharma. "Because of Tollovid status as a dietary
supplement on the market in the United
States, we have a tremendous strategic advantage over
competitors in Long COVID because we are in the position of being
able to listen to the patients first hand describing how Tollovid
supplementation, alone or sometimes in combination with other
products, is helping them and apply this knowledge to our formal
Tollovir Long COVID drug development plans."
Respondents to the market research survey generally followed the
directions on the Tollovid label, taking 12 capsules per day for 5
days among Acute COVID respondents, and taking at least 2 bottles
of Tollovid according to the directions among Long COVID
respondents. This market research study is not designed to assess
optimal Tollovid dosing. No negative effects from interactions with
other concomitant medications or supplements were reported by
survey respondents.
To purchase Tollovid please visit Amazon or
http://www.MyTollovid.com.
About Tollovid® and Tollovid Daily™
Tollovid and Tollovid Daily are dietary supplement products made
from natural ingredients that help support and maintain healthy
immune function and also have potent 3CL protease inhibition
properties based upon in vitro functional assays that show strong
inhibition of 3CL protease activity. Tollovid's 3CL protease IC50
binding affinity is at least ten times (10x) as strong as
Ivermectin's published 3CL protease IC50 binding affinity. Tollovid
Daily's 3CL protease IC50 binding affinity is at least two and a
half times (2.5x) as Ivermectin. Tollovid and Tollovid Daily bind
to the active site (receptor binding domain) of the 3CL protease.
Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken
each day that provides maximum immune support. Tollovid Daily is a
daily immune support product with a dosing regimen of twice
daily.
About Tollovir®
Tollovir® is a 3CL protease inhibitor and anti-cytokine
therapeutic candidate for the intervention of the Nidovirus group
of viruses that includes coronaviruses such as SARS-CoV-2,
COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all
natural ingredients that are qualified to ensure strong inhibition
of the 3CL protease in vitro, as well as strong anti-cytokine
activity. Tollovir has successfully completed a Phase 2 clinical
trial in Israel for the treatment
of patients hospitalized with COVID-19. Tollovir will be developed
for the treatment of hospitalized COVID-19 (severe and critical),
moderate COVID-19, long-haul COVID and potentially pediatric
COVID-19. Todos has licensed rights for Tollovir to T-Cell Protect
Hellas S.A. for the Greek market.
About Todos Medical Ltd.
Founded in Rehovot, Israel with
offices in New York City, Todos
Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic
solutions for the early detection of a variety of cancers. The
Company's state-of-the-art and patented Todos Biochemical Infrared
Analyses (TBIA) is a proprietary cancer-screening technology using
peripheral blood analysis that examines cancer's influence on the
immune system, looking for biochemical changes in blood mononuclear
cells and plasma. Todos' two internally developed cancer-screening
tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based
medical diagnostics company Provista Diagnostics, Inc. to gain
rights to its Alpharetta,
Georgia-based CLIA/CAP certified lab currently performing
PCR COVID testing and Provista's proprietary commercial-stage
Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of
neurodegenerative disorders, such as Alzheimer's disease. The
Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood
test that determines the ability of peripheral blood lymphocytes
(PBLs) and monocytes to withstand an exogenous mitogenic
stimulation that induces them to enter the cell cycle. It is
believed that certain diseases, most notably Alzheimer's disease,
are the result of compromised cellular machinery that leads to
aberrant cell cycle re-entry by neurons, which then leads to
apoptosis. LymPro is unique in the use of peripheral blood
lymphocytes as a surrogate for neuronal cell function, suggesting a
common relationship between PBLs and neurons in the brain.
Todos formed the Israeli-based majority-owned joint venture 3CL
Pharma, Ltd with NLC Pharma in March of 2022 to consolidate all of
the intellectual property pursuing the development of diagnostic
tests targeting the 3CL protease, as well as 3CL protease inhibitor
botanical and pharmaceutical products that target a fundamental
reproductive mechanism of coronaviruses. 3CL Pharma, through Todos'
brand, has commercialized the 3CL protease inhibitor immune support
dietary supplement Tollovid® in the
United States, is developing the dual mechanism 3CL protease
inhibitor & anti-cytokine therapeutic drug candidate Tollovir®,
while also developing the 3CL protease inhibitor diagnostic
TolloTest™.
For more information, please visit
https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may
constitute forward-looking statements. For example, forward-looking
statements are used when discussing our expected clinical
development programs and clinical trials. These forward-looking
statements are based only on current expectations of management,
and are subject to significant risks and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval or patent protection for
product candidates; competition from other biotechnology companies;
and our ability to obtain additional funding required to conduct
our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual
results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from the
competition; and laboratory results that do not translate to
equally good results in real settings, all of which could cause the
actual results or performance to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Todos Medical does not undertake any
obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Todos Medical, please refer to its reports
filed from time to time with the U.S. Securities and Exchange
Commission.
Media Contact
Ruth Davis, Americas Next
Investment, 1 800-249-4204,
ruth.davis@americasnextinvestment.com
SOURCE Todos Medical Ltd.